

Applicants: David M. Stern et al.
U.S. Serial No.: 09/687,528
Filing Date: October 13, 2000
Page 2

Please amend the subject application as follows:

In the claims:

Please cancel claims 1-2, 7-8, 10 and 15-24 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a later filed application. Please also amend claims 4-5, 9, 11 and 13-14 under the provisions of 37 C.F.R. § 1.121(c) as follows. A marked up version of amended claims 4-5, 9, 11 and 13-14 wherein the deleted material is in brackets and the inserted material is underlined is attached hereto as Exhibit A.

--4. (Amended) The method of claim 3, wherein the subject is a human.--

a' --5. (Amended) The method of claim 3, wherein the subject has undergone an angioplasty procedure or has undergone surgery to implant a stent in a blood vessel.--

a² --9. (Amended) The method of claim 3, wherein the inhibitor is the V-domain of soluble receptor for advanced glycation endproduct (sRAGE).--

a³ --11. (Amended) The method of claim 3, wherein the inhibitor is administered to the subject by bolus injection, intraperitoneal injection, i.v., oral administration, topical application to the blood vessel, coating of a device to be placed within the